EBS News and Press, Emergent Biosolutions Inc. From 10/10/19

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for M...

GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2019, recent business developments, revenue guidance for...

Shares of Emergent BioSolutions (NYSE: EBS) jumped 19.4% in September, according to data provided by S&P Global Market Intelligence, after the bioterrorism expert was awarded a contract from the U.S. Department of Health and Human Services to buy approximately $2 billion worth of its s...

Wells Fargo names Emergent BioSolutions (NYSE: EBS ) as one of its top healthcare picks for the remainder of the year. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Read more ...

Emergent BioSolutions (NYSE: EBS ) is awarded a research grant of ~$6.3M over two years by the National Institute on Drug Abuse (NIDA), for the continued development of AP007, the company’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder...

GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued ...

GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4. ...

The U.S. Department of Defense has awarded $20M to Emergent BioSolutions (NYSE: EBS ) to develop an auto-injector containing diazepam (5 mg/mL) to treat agent-induced seizures. The product will designed for intramuscular injection by a "buddy" in military environments and in civilian emerg...

GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s ...

The Food and Drug Administration really wants to see an over-the-counter (OTC) version of the opioid overdose medication naloxone -- so much so that it's doing the legwork needed to get the ball rolling. In a statement on Friday, the agency noted: In January, we took an unprecedented step in h...